DOT1L and leukemia: Next, we tested whether SYC-522 inhibited the expression of MLL-fusion target genes HOXA9 and MEIS1, both of which have been found to be overexpressed in MLL-rearranged leukemia [23], [24] and downregulated by treatment with a DOT1L inhibitor [18].